Reprint

Integrating Clinical and Translational Research Networks—Building Team Medicine - Series 2

Edited by
August 2023
230 pages
  • ISBN978-3-0365-8472-0 (Hardback)
  • ISBN978-3-0365-8473-7 (PDF)

This is a Reprint of the Special Issue Integrating Clinical and Translational Research Networks—Building Team Medicine - Series 2 that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

The previous Special Issue of the Journal of Clinical Medicine, ‘Integrating Clinical and Translational Research Networks—Building Team Medicine’, which highlighted our collective experience from the City of Hope and was published in 2020, was a huge success. Buoyed by the enthusiastic response from our peers and colleagues, we have embarked on bringing out Volume 2. The basic theme is the same—namely, integrating academic medical centers with the clinical network in various geographic locations to ensure that all patients, regardless of their physical proximity to major medical institutions, can benefit from recent clinical advances. As in the previous volume on the importance of including basic research scientists, our aim here is to highlight translational research approaches that leverage the combined knowledge, skills, experience, expertise, and vision of clinicians in academic medical centers, their affiliated community centers, and hospitals, together with those of basic research scientists. However, here we also strive to include bioinformaticians and data scientists. We look forward to sharing our team medicine experience with our colleagues around the world and trust that they will find the approach described in the articles included in this Special issue useful for guiding their approaches for treating cancer patients.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
drug resistance; drug tolerance; eco-evolutionary; intermittent therapy; adaptive therapy; continuous therapy; Team Medicine; intrinsically disordered proteins; complex case discussions; decision support; oncology pathways; personalized medicine; subspecialty expertise; colorectal cancer survivor; emergency utilization; SARS-CoV-2; care satisfaction; pandemic; drug resistance; cisplatin; non-small cell lung cancer; group behavior; IDPs; phenotype switching; mathematical modeling; oncolytic virotherapy; T-VEC; immune checkpoint inhibitors; immunotherapy; targeted therapy; combinational therapy; melanoma; cutaneous cancers; clinical trials; neuroendocrine tumors; self-assessment; NET VITALS; implementation science; tobacco control; smoking cessation; cancer prevention; lung cancer screening; low dose Ct scans; LDCT; cancer disparities; minority health; personalized medicine; pathways to success; renal cell carcinoma; gut microbiome; translational research; EGFR; non-small cell lung cancer; drug resistance; genetic/nongenetic; epigenetics; oligometastatic; prostate cancer; metastasis-directed therapy; imaging; PSMA PET; advanced soft tissue sarcoma; sarcoma treatment; Midwest Sarcoma Trials Partnership; targeted therapy; multidisciplinary tumor board; collaboration; endometrial cancer; PARP inhibition; pathologic complete response; Olaparib; BRIP1 mutation; ATM mutation; RAD51C mutation; POLE mutation; TMB high; brain metastases; delivery of health care; leptomeningeal metastases; tumor board; integrative oncology; clinical care network; implementation; integration; community clinical network; phase 1; genomic-driven; clinical trials; team medicine; precision medicine; cancer systems biology; clinical network systems biology; artificial intelligence; City of Hope; oncology; community practice; n/a